In December, Primary Care Optometry News quoted me in an article about central serous chorioretinopathy. The article talked about a lot of facets of the disease, and one of them was a new oral treatment with eplerenone.

This is a fairly new treatment, and since the article ran I’ve gotten some good questions and comments from eye doctors who read it and were curious about it. So, I wanted to use this month’s post to dig deeper into this medication and how it works for treating central serous chorioretinopathy (CSCR).